%0 Journal Article
%T Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia
%A Misako Matsumoto
%A Tsukasa Seya
%A Yohei Takeda
%J Archive of "Oncoimmunology".
%D 2016
%R 10.1080/2162402X.2015.1043506
%X Here, we introduce a double-stranded RNA mimic that is chemically synthesized to exclusively stimulate toll-like receptor 3 (TLR3). This function-defined TLR3 ligand, named ARNAX, acts as an adjuvant to induce antitumor CTL and NK without significant cytokinemia in mice, and thus superior to polyI:C for therapeutic vaccine immunotherapy against tumor
%K Antitumor CTL
%K Priming-phase adjuvant
%K no cytokine toxicity
%K tumor remission
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801468/